Overview

Detailed Summary

Clinitech Laboratory Limited is a provider of diagnostic and healthcare tests and services through a chain of 8 diagnostic centers around Thane, Raigad, and Navi Mumbai.
The company performs over 300,000 tests annually, including a wide range of laboratory diagnostics like biochemistry, immunology, and molecular biology in NABL-accredited labs.
Clinitech recently changed its status to a public limited company and has announced an initial public offering (IPO) to raise Rs 5.79 Crores by issuing new equity shares.
The company has consistently expanded its diagnostic capabilities, adding new labs in regions like Kalyan and Thane over the past decade to cater to growing demand.
Incorporated on March 19, 2010, Clinitech benefits from its promoters' 30+ years of experience in the diagnostic business, contributing to its strong regional reputation.

Sector: Healthcare Services
Industry: Healthcare Service Provider
Market Cap: 9 Cr
Volatility: High Risk
P/E Ratio: 21.7
Industry P/E: 64.9
PEG Ratio: 4.0
P/B Ratio: 1.0
52W High: 57.00
52W Low: 28.55

Sales CAGR

1Y: 28.59%
3Y: 8.85%
5Y: —
10Y: —

Profit CAGR

1Y: 5.41%
3Y: -8.34%
5Y: —
10Y: —

ROE

TTM: 4.52%
3Y: 9.34%
5Y: 12.75%
10Y: —

ROCE

TTM: 6.80%
3Y: 12.32%
5Y: 16.26%
10Y: —

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ZDHJERK		24.24	10 Cr	25.46	0.95	0.00	3.81	3.50	2.22
LOOKS		9.40	10 Cr	329.00	0.66	0.00	0.16	0.21	0.19
CTLLAB		40.00	9 Cr	21.74	0.99	0.00	4.52	6.80	3.67
DLCL		7.98	7 Cr	95.86	0.47	0.00	0.45	0.71	0.40
TATIASKYLN		5.02	6 Cr	-50.17	0.54	0.00	-1.16	0.77	-0.80
GIANLIFE		4.93	5 Cr	-5.29	0.27	0.00	-3.76	-1.02	-2.81
BOSTONBIO		4.73	3 Cr	-5.71	0.62	0.00	-10.91	0.16	-7.87
Median: 7 Co.	—	7.98	7 Cr	21.74	0.62	0.00	0.16	0.71	0.19

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Half Yearly Results (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2025	Sep 2025	Mar 2026
Sales	4.16	5.08	4.41
Expenses	3.88	4.54	3.96
Interest	0.02	0.05	0.02
Operating Profit	0.28	0.54	0.45
OPM %	6.73	10.63	10.20
Other Income	0.17	0.11	0.08
Depreciation	0.14	0.25	0.26
Profit Before Tax	0.30	0.35	0.25
Tax %	40.00	14.29	52.00
Net Profit	0.17	0.30	0.11
EPS in Rs	—	—	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	4.55	6.38	6.35	6.40	8.23
Expenses	3.73	5.32	5.00	5.42	7.40
Operating Profit	0.82	1.07	1.35	0.98	0.83
OPM %	18.10	16.71	21.28	15.31	10.10
Other Income	0.04	0.07	0.02	0.04	0.23
Interest	0.08	0.06	0.06	0.07	0.06
Depreciation	0.25	0.38	0.45	0.44	0.45
Profit Before Tax	0.55	0.70	0.86	0.51	0.55
Tax %	26.26	27.00	29.01	26.52	28.84
Net Profit	0.40	0.51	0.61	0.37	0.39
EPS in Rs	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.67	1.50	1.50	1.68	2.28
Reserves	0.72	0.35	0.88	1.87	6.55
Borrowings	0.54	0.89	1.03	0.86	0.00
Other Liabilities	0.81	0.95	2.62	1.20	1.88
Total Liabilities	2.73	3.69	6.03	5.61	11
Fixed Assets	0.84	1.65	1.33	1.71	2.12
CWIP	0.08	0.41	0.56	0.94	1.01
Investments	0.09	0.14	2.02	0.07	0.07
Other Assets	1.72	1.49	2.12	2.88	7.51
Total Assets	2.73	3.69	6.03	5.61	11

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.38	0.96	1.25	0.11	-0.88
Cash from Investing Activity	0.54	-1.47	-0.65	-0.64	-0.73
Cash from Financing Activity	-0.88	0.29	0.09	0.45	3.98
Net Cash Flow	0.04	-0.22	0.68	-0.08	2.37

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jan 2024	Jul 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026
Promoters	83.63%	61.58%	61.58%	61.58%	62.42%	64.20%
FIIs	0.00%	0.32%	0.32%	0.32%	0.32%	0.32%
DIIs	16.37%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	0.00%	38.11%	38.11%	38.11%	37.27%	35.48%
Total Shareholders	24	450	346	303	303	297

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Clinitech Laboratory Ltd

Clinitech Laboratory Ltd (CTLLAB) is currently trading at 40.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Clinitech Laboratory Limited is a provider of diagnostic and healthcare tests and services through a chain of 8 diagnostic centers around Thane, Raigad, and Navi Mumbai. The company performs over 300,000 tests annually, including a wide range of laboratory diagnostics like biochemistry, immunology, and molecular biology in NABL-accredited labs. Clinitech recently changed its status to a public limited company and has announced an initial public offering (IPO) to raise Rs 5.79 Crores by issuing new equity shares. The company has consistently expanded its diagnostic capabilities, adding new labs in regions like Kalyan and Thane over the past decade to cater to growing demand. Incorporated on March 19, 2010, Clinitech benefits from its promoters' 30+ years of experience in the diagnostic business, contributing to its strong regional reputation.

Over the past 52 weeks, Clinitech Laboratory Ltd has traded between a low of ₹28.55 and a high of ₹57.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Clinitech Laboratory Ltd has a market capitalization of approximately 9.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Clinitech Laboratory Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 9.13 Cr, Clinitech Laboratory Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Clinitech Laboratory Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Clinitech Laboratory Ltd is 21.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

A board meeting was held on February 06, 2026, and it ran from 03:00 PM IST to 03:20 PM IST, with a disclosed duration of 20 minutes.

Clinitech Laboratory Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison